Stockchase Opinions

Michael Smedley NUCRYST Pharmaceuticals Corp. NCS-T PAST TOP PICK Aug 03, 2007

(A Top Pick Aug 24/06. Down 79.5%.) Their cream for treating acne did not get approved by the FDA, but did get approval 2 weeks ago. It might still be interesting. Sold his holdings.
$2.960

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK
The Silcryst bandaging spin off from Westaim (WED-T). (They still hold about 75%). Have developed/patented a technology for reducing nanotechnology silver to its crystalline level for application in ointments. Getting great revenues. Highly speculative.
PAST TOP PICK
(A Top Pick Aug 24/06. Down 52%.) Something went wrong with silver ointment treatment. They are back with silver bandaging. Based on the bandaging, it will be trading at 8-9 X earnings.
DON'T BUY
Their acne treatment was not approved previously by the FDA, but suddenly was in July.. The approval isn’t doing a great deal for it.